Amgen Inc struck a more than $10 billion deal to purchase Onyx Pharmaceuticals Inc on Sunday, ending a two-month-long auction for the cancer drugmaker. Amgen said it will pay $125 per share for Onyx, a 4.2 percent increase from the $120 a share it offered to pay in June. Onyx said that bid significantly undervalued the company and put itself up for sale.The deal represents the fifth-largest biotechnology deal in history and gives Amgen full rights to Kyprolis, the new multiple myeloma drug that analysts expect to reach annual peak sales in excess of $2 billion.
Amgen Inc. is a global biotechnology pioneer that discovers, develops, manufactures and delivers human therapeutics. Shares of AMGN fell by 0.65% or $-0.69/share to $105.60. In the past year, the shares have traded as low as $80.60 and as high as $114.95. On average, 3248110 shares of AMGN exchange hands on a given day and today's volume is recorded at 1572216.
Onyx Pharmaceuticals, Inc. (Onyx) is a biopharmaceutical company. Shares of ONXX fell by 0.54% or $-0.63/share to $116.96. In the past year, the shares have traded as low as $68.12 and as high as $136.87. On average, 2289700 shares of ONXX exchange hands on a given day and today's volume is recorded at 1236300.
Source
